Lin28a ameliorates glucotoxicity-induced β-cell dysfunction and apoptosis

Area of Science:

• Cell Biology
• Endocrinology
• Molecular Biology

Background:

• Glucotoxicity, caused by prolonged high glucose, leads to beta-cell dysfunction and impaired insulin secretion.
• Lin28a and Lin28b are known regulators of glucose metabolism, but their protective mechanisms against glucotoxicity are not fully understood.

Purpose of the Study:

• To investigate the protective role of Lin28a overexpression against glucotoxicity-induced beta-cell dysregulation.
• To elucidate the molecular mechanisms underlying Lin28a's protective effects in pancreatic beta cells.

Main Methods:

• In vitro and ex-vivo experiments using INS-1 cells and primary rat islet cells.
• Adenovirus-mediated Lin28a overexpression and small interfering RNA (siRNA) for Lin28a inhibition.
• Analysis of insulin synthesis/secretion, beta-cell transcription factors (PDX-1, BETA2), apoptosis markers (c-caspase3, Bax/Bcl-2), and signaling pathways (PI3K/Akt/mTOR).

Main Results:

• Chronic high glucose downregulated Lin28a, reduced insulin expression/secretion, and increased apoptosis.
• Lin28a overexpression reversed these effects, restoring insulin levels and reducing apoptosis.
• Lin28a regulated PDX-1 and BETA2, inhibited apoptosis via the PI3K/Akt/mTOR pathway, and counteracted the downregulation of p-Akt and p-mTOR.

Conclusions:

• Lin28a overexpression protects pancreatic beta cells against glucotoxicity.
• Lin28a exerts its protective effects by inhibiting apoptosis and modulating the PI3K/Akt/mTOR signaling pathway.
• Lin28a is a potential therapeutic target for managing glucotoxicity-related beta-cell dysfunction.